SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?

• A. Inadequate training
• B. Causes of non-conformities
• C. Late and/or incorrect deliverables
• D. Adverse environmental impacts

The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?

• A. Confirm that the international monograph change is not related to local pharmacopeia.
• B. Transfer the notice of the upcoming international monograph change to QA for further processing.
• C. Prepare the international monograph change submission first and then prepare the local change when required.
• D. Analyze the impact of the international monograph change on the local pharmacopeia.

Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?

• A. Train all new employees on regulatory compliance processes and assign a mentor to them.
• B. Document any failure to follow regulatory compliance processes in employee performance reviews.
• C. Develop documented procedures for regulatory compliance processes and train personnel.
• D. Train employees on all regulatory compliance processes using state-of-the-art systems.

Company X and Company Y both have products for the treatment of rare genetic diseases.
Company X would like to acquire Company Y but does not know enough about Company Y to make an offer.
What is the MOST appropriate approach that Company X should take to acquire more information about Company Y?

• A. Recruit a professional to gather confidential intelligence on Company Y.
• B. Perform a thorough library search to gather detailed information on Company Y.
• C. Enter into an agreement with Company Y to perform due diligence.
• D. Request the needed information from the Board of Directors of Company Y.

A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?

• A. The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.
• B. The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.
• C. The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.
• D. The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.